Effects of body habitus on contrast-induced acute kidney injury after percutaneous coronary intervention

Toshiki Kuno1,2*, Yohei Numasawa1, Mitsuaki Sawano3, Toshiomi Katsuki3, Masaki Kodaira1, Ikuo Ueda3, Masahiro Suzuki4, Shigetaka Noma5, Koji Negishi6, Shiro Ishikawa7, Hiroaki Miyata8, Keiichi Fukuda3, Shun Kohsaka3

1 Department of Cardiology, Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan, 2 Department of Medicine, Mount Sinai Beth Israel Medical Center, New York, NY, United States of America, 3 Department of Cardiology, Keio University School of Medicine, Tokyo, Japan, 4 Department of Cardiology, Saitama National Hospital, Wako, Japan, 5 Department of Cardiology, Saiseikai Utsunomiya Hospital, Utsunomiya, Japan, 6 Department of Cardiology, Yokohama Municipal Citizens’ Hospital, Yokohama, Japan, 7 Department of Cardiology, Saitama City Hospital, Saitama, Japan, 8 Department of Health Policy and Management, Keio University, Tokyo, Japan

* Toshiki.Kuno@mountsinai.org

Abstract

Background
Limiting the contrast volume to creatinine clearance (V/CrCl) ratio is crucial for preventing contrast-induced acute kidney injury (CI-AKI) after percutaneous coronary intervention (PCI). However, the incidence of CI-AKI and the distribution of V/CrCl ratios may vary according to patient body habitus.

Objective
We aimed to identify the clinical factors predicting CI-AKI in patients with different body mass indexes (BMIs).

Methods
We evaluated 8782 consecutive patients undergoing PCI and who were registered in a large Japanese database. CI-AKI was defined as an absolute serum creatinine increase of 0.3 mg/dL or a relative increase of 50%. The effect of the V/CrCl ratio relative to CI-AKI incidence was evaluated within the low- (<25 kg/m²) and high- (>25 kg/m²) BMI groups, with a V/CrCl ratio > 3 considered to be a risk factor for CI-AKI.

Results
A V/CrCl ratio > 3 was predictive of CI-AKI, regardless of BMI (low-BMI group: odds ratio [OR], 1.77 [1.42–2.21]; P < 0.001; high-BMI group: OR, 1.67 [1.22–2.29]; P = 0.001). The relationship between BMI and CI-AKI followed a reverse J-curve relationship, although baseline renal dysfunction (creatinine clearance < 60 mL/min, 46.9% vs. 21.5%) and V/CrCl ratio > 3 (37.3% vs. 20.4%) were predominant in the low-BMI group. Indeed, low BMI was a
A V/CrCl ratio > 3 was strongly associated with the occurrence of CI-AKI. Importantly, we also identified a tendency for physicians to use higher V/CrCl ratios in lean patients. Thus, recognizing this trend may provide a therapeutic target for reducing the incidence of CI-AKI.

Introduction

Contrast-induced acute kidney injury (CI-AKI) in patients undergoing percutaneous coronary intervention (PCI) is common and is associated with an increased risk of mortality during and after hospitalization [1,2]. Considering the high mortality rate associated with CI-AKI, numerous large studies have attempted to identify factors that predict CI-AKI. Among the identified factors, minimizing contrast agent volume (CV) is a proven strategy for lowering the risk of CI-AKI [3]. Clinical guidelines, therefore, recommend reducing the contrast volume to creatinine clearance (V/CrCl) ratio during PCI [4,5]. The predicted CV, however, may vary depending on patient-specific characteristics, including the individual’s body mass index (BMI, kg/m²), with higher rates of CI-AKI reported in lean patients [6]. However, the V/CrCl ratio that is predictive of CI-AKI among patients with different BMIs has not been definitively determined.

Accordingly, this study investigated the relationship between BMI and CI-AKI, and quantified the V/CrCl ratio predictive of CI-AKI among patients with low and high BMIs. In addition, we investigated the association between a V/CrCl ratio less than 3 and BMI; a previous study determined that a V/CrCl ratio of 3 was a reasonable cut-off value [7]. The identification of clinical factors predictive of CI-AKI in patients with various BMIs is clinically important because they would provide potential therapeutic targets that might reduce the incidence of CI-AKI and inform clinical decisions regarding the optimal CV for a patient.

Materials and methods

The Japanese Cardiovascular Database-Keio inter-hospital Cardiovascular Studies (JCD-KiCS) is a large, ongoing, multicenter, prospective cohort study designed to collect clinical background and outcome data for consecutive patients undergoing PCI. The Institutional Review Board of Keio University School of Medicine as well as each participating hospital approved the JCD-KiCS registry study protocol. The study was carried out in accordance with the approved guidelines and the Declaration of Helsinki. Before the launch of the registry, the objectives of the present study, its social significance, and an abstract were provided for clinical trial registration with the University hospital Medical Information Network (UMIN), which is recognized by the International Committee of Medical Journal Editors as an “acceptable registry” according to a statement issued in September 2004 (UMIN R000004736). UMIN is the largest and most versatile academic network information center for biomedical sciences in the world, and it is now considered as an indispensable information infrastructure for the Japanese medical community (http://www.umin.ac.jp/english/whatisumin.htm). Further, written informed consent was obtained from each patient before being included in the study. The data collection procedures and audit processes for the JCD-KiCS have been previously described,
The majority of the clinical variables included in the JCD-KiCS were defined according to the National Cardiovascular Data Registry (NCDR), sponsored by the American College of Cardiology [17–19].

We analyzed the data for 8782 consecutive patients who underwent PCIs, between April 2011 and March 2016, across the 15 Japanese hospitals participating in the JCD-KiCS (Fig 1); patients with missing values, such as those for creatinine, CV, and BMI, were excluded. The baseline characteristics and in-hospital outcomes of the excluded patients are shown in S1 and S2 Tables.

In our registry, fifteen hospitals from the Tokyo, Tochigi, Saitama, Chiba, and Kanagawa Prefectures of Japan participated. The participating hospitals included 12 large, tertiary care, referral centers (>200 beds) and 3 mid-sized satellite hospitals (<200 beds). Among these hospitals, the average annual case volume was approximately 228. Between 2013 and 2016, we limited data registration to the 4 high-volume centers (N = 5749 among 12,579 cases), with an average case volume of 479. These numbers are not dissimilar from the median PCI cases/year across all the hospitals in Japan (median, 216; interquartile range [IQR], 121–332) [20].

The relationship between CI-AKI development and BMI was investigated, first. Then, patients were divided into 2 BMI groups: those with BMIs ≤25 kg/m² (low-BMI group, N=5499, 62.6%) and BMI >25: high-BMI group, N=3283 (37.4%).
n = 5499, 62.6%) and those with BMIs >25 kg/m² (high-BMI group, n = 3283, 37.4%) (Fig 1). The baseline characteristics and in-hospital outcomes, including the numbers of patients developing CI-AKI, for each group were evaluated. Creatinine clearances (CrCls) were calculated using the Cockcroft-Gault formula [7,21]. In addition, to assess V/CrCl ratio variations relative to CI-AKI risk, we investigated the CI-AKI risk and mean V/CrCl ratio for all patients in both groups; our registry incorporated the validated NCDR AKI risk model [22,23].

CI-AKI was defined as an absolute increase in serum creatinine values of 0.3 mg/dL or a relative increase of 50%, in accordance with the Acute Kidney Injury Network criteria [23,24]. In the JCD-KiCS registry, the post-procedural creatinine values were defined as the highest values within 30 days after the index procedure. Congruent with the NCDR definition, if more than 1 post-procedural creatinine level was measured, the highest value was used for determining CI-AKI. The timing of the creatinine measurements in the core hospital center (Keio University Hospital; n = 979) showed that most such measurements were made during the first post-PCI day [23]. The timing of the peak creatinine level was also congruent with that in other previously published studies [25].

PCI-related complications were defined using a composite endpoint that included severe flow-limiting coronary dissection or coronary perforation, myocardial infarction after PCI, cardiogenic shock or heart failure, cerebral bleeding or stroke, and other bleeding complications. Bleeding complications were defined as those requiring transfusion, prolonging hospital stay, and/or causing a decrease in hemoglobin of >3.0 g/dL [26]. When present, bleeding complications were classified using the bleeding site: puncture-site bleeding (including external bleeding or a hematoma diameter >10 cm [femoral], >5 cm [brachial], or >2 cm [radial] at the access site), retroperitoneal bleeding, gastrointestinal bleeding, genitourinary bleeding, or other types of bleeding. This bleeding complication definition is consistent with that for a grade 3 (A–C) bleed, according to the Bleeding Academic Research Consortium [27]. Our definitions of complications were also consistent with the NCDR CathPCI registry; additional information on data elements and definitions is available on their web site: http://www.ncdr.com/webncdr/cathpci/.

Continuous variables are expressed as means and standard deviations or medians (IQR), as appropriate for the data distribution; categorical variables are expressed as percentages. For continuous variables, changes from baseline were evaluated using Student’s t test or the Mann-Whitney U-test, as appropriate for the data distribution; chi-squared or Fisher’s exact tests were used for assessing changes in categorical variables. Smooth spline plots were used to analyze correlations between BMI and CI-AKI, and between BMI and the V/CrCl ratio. A multivariate logistic regression analysis evaluated the effect of BMI on the incidence of a V/CrCl ratio > 3 (V/CrCl > 3). Variables with P-value < 0.25 in the univariate modeling were included in a multivariate logistic regression model to identify factors associated with V/CrCl > 3. To assess CI-AKI using the logistic regression model in each BMI group, the following variables were entered: female gender, previous heart failure, diabetes mellitus, peripheral artery disease, hypertension, smoking, previous PCI, heart failure upon admission, cardiogenic shock upon admission, cardiopulmonary arrest upon admission, femoral artery approach, intra-aortic balloon pump, ST-elevation myocardial infarction, non ST-elevation myocardial infarction, unstable angina, type C lesion, use of intravascular ultrasound, BMI, age, and V/CrCl > 3.

We performed two sensitivity analyses. The first was a multivariate logistic regression analysis to assess the association of BMI with V/CrCl > 3, excluding the 3832 patients with complex lesions (PCI of the left main coronary artery, type C lesion, bifurcation lesion, chronic total occlusion lesion, Rotablator use, multivessel PCI) because lesion complexity may affect CV [28,29]. Second, we analyzed associations with CV, V/CrCl ratio, and BMI for the 3283
patients with a CrCl <60 mL/min (indicative of a high CI-AKI risk) in a subgroup analysis [22,30].

All statistical calculations and analyses were performed using SPSS (version 24, SPSS, Chicago, IL, USA), and R 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria); P-values < 0.05 were considered statistically significant.

Results

The mean age of the patients in our study group was 68.3 ± 11.2 years; they had a mean BMI of 24.3 ± 3.7 kg/m². Among the study participants, 48.8% presented with acute coronary syndrome. The overall incidence of CI-AKI was 9.5% (n = 838), with an in-hospital mortality rate of 1.7% (n = 153).

The in-hospital outcomes for both BMI groups are summarized in Table 1. The incidences of CI-AKI were comparable between the groups (9.5% for each group). In both BMI groups, significant associations were observed between V/CrCl > 3 and CI-AKI in the logistic regression modeling. The odds ratios [ORs] of CI-AKI occurring in the presence of V/CrCl > 3 were 1.77 (95% confidence interval [CI], 1.42–2.21; P < 0.001) for the low-BMI group and 1.67 (95% CI, 1.22–2.29, P = 0.001) for the high-BMI group (Tables 2 and 3). Other clinical factors associated with CI-AKI for the low- and high-BMI groups are also reported in Tables 2 and 3.

The baseline characteristics of patients in the low- and high-BMI groups, including procedural information, are summarized in Table 1. The BMI and CI-AKI incidence data demonstrated a reverse J-curve relationship (Fig 2). Overall, the low-BMI group included older patients and had a higher proportion of females than did the high-BMI group. Importantly, the proportion of patients with renal dysfunction (CrCl < 60 mL/min.) was also higher in the low-BMI group than in the high-BMI group (46.9% vs. 21.5%, P < 0.001), although the creatinine values were similar between the two groups (low-BMI group, 0.9 [0.7, 1.1] mg/dL; high-BMI group, 0.9 [0.7, 1.1] mg/dL, P = 0.068). Additionally, the proportion of patients with a V/CrCl > 3 was higher in the low-BMI (37.3%) group than in the high-BMI (20.4%) group (P < 0.001) and the V/CrCl ratios were significantly different between the groups (low-BMI, 2.5 [1.8, 3.6]; high-BMI, 1.9 [1.3 vs. 2.8]; P < 0.001). The smooth spline plots showed the inverse relationship between the V/CrCl ratio and BMI (Fig 3).

Since the smooth spline plots revealed higher V/CrCl ratios in patients in the low-BMI group, we sought to identify the effect of BMI on the incidence of V/CrCl > 3 observations. Using a multivariate logistic regression analysis, a low BMI was as a significant predictor of a V/CrCl > 3 (OR, for 1 unit decrease in BMI, 1.04; 95% CI, 1.05–1.10; P < 0.001; Table 4). In the all-patient analysis of CI-AKI risk and V/CrCl ratio, patients with a higher CI-AKI risk tended to have higher V/CrCl ratios, particularly those in the low-BMI group (Fig 4).

In a sensitivity analysis of patients, excluding those with complex lesions, the BMI tended to remain predictive of V/CrCl > 3 (OR, for 1 unit decrease in BMI, 1.04; 95% CI, 1.01–1.07; P = 0.07). In a second sensitivity analysis of patients with CrCl < 60 mL/min, the CV administered in each group was similar (low-BMI group vs. high-BMI group, 155 ± 73 mL vs. 154 ± 82 mL; P = 0.72), whereas the V/CrCl ratios were quite different between the groups (3.4 [2.5, 4.8] vs. 3.0 [2.2, 4.2], respectively, P < 0.001). After performing a multivariate logistic regression analysis for this subgroup, BMI remained a significant predictor of V/CrCl > 3 (OR, for 1 unit decrease in BMI, 1.07; 95% CI, 1.05–1.10; P < 0.001) risk.

Discussion

The major findings from our study are as follows. First, V/CrCl > 3 was strongly associated with CI-AKI incidence, regardless of patient BMI. Second, the relationship between BMI and
Table 1. Baseline characteristics and in-hospital outcomes for all patients.

| Characteristic                          | BMI ≤ 25 n = 5499 (62.6%) | BMI > 25 n = 3283 (37.4%) | P-value |
|----------------------------------------|-----------------------------|-----------------------------|---------|
| Age, y                                 | 70.3 ± 10.5                 | 64.8 ± 11.5                 | <0.001  |
| Females, n (%)                         | 1252 (22.8)                 | 580 (17.7)                  | <0.001  |
| BMI (kg/m²)                            | 22.1 ± 2.1                  | 27.9 ± 2.8                  | <0.001  |
| Creatinine value (mg/dL)               | 0.9 [0.7, 1.1]              | 0.9 [0.7, 1.1]              | 0.068   |
| Creatinine clearance (mL/min.)         | 64.1 ± 26.9                 | 88.7 ± 36.1                 | <0.001  |
| Creatinine clearance < 60 mL/min, n (%)| 2578 (46.9)                 | 705 (21.5)                  | <0.001  |
| Diabetes mellitus with insulin, n (%)  | 348 (6.3)                   | 268 (8.2)                   | 0.001   |
| Chronic lung disease, n (%)            | 514 (9.3)                   | 237 (7.2)                   | 0.001   |
| Peripheral artery disease, n (%)       | 555 (10.1)                  | 212 (6.5)                   | <0.001  |
| Hypertension, n (%)                    | 3909 (71.1)                 | 2610 (79.5)                 | <0.001  |
| Smoking, n (%)                         | 1697 (30.9)                 | 1293 (39.4)                 | <0.001  |
| Dyslipidemia, n (%)                    | 3383 (61.5)                 | 2382 (72.6)                 | <0.001  |
| Previous PCI, n (%)                    | 1913 (34.8)                 | 1280 (39.0)                 | <0.001  |
| Heart failure on admission, n (%)      | 721 (13.1)                  | 298 (9.1)                   | <0.001  |
| Previous coronary bypass, n (%)        | 291 (5.3)                   | 138 (4.2)                   | 0.022   |
| Diabetic shock upon admission, n (%)   | 253 (4.6)                   | 111 (3.4)                   | 0.006   |
| Cardiopulmonary arrest upon admission, n (%) | 144 (2.6)                   | 82 (2.5)                    | 0.729   |
| PCI indication                         |                             |                             | <0.001  |
| ST-elevation myocardial infarction, n (%) | 1424 (25.9)                | 756 (23.0)                  |         |
| Non-ST-elevation myocardial infarction, n (%) | 473 (8.6)                 | 241 (7.3)                   |         |
| Unstable angina, n (%)                 | 896 (16.3)                  | 500 (15.2)                  |         |
| Elective PCI, n (%)                    | 2706 (49.2)                 | 1786 (54.4)                 |         |
| 3-vessel disease, n (%)                | 1095 (19.9)                 | 647 (19.7)                  | 0.816   |
| PCI artery (%)                         |                             |                             |         |
| Left main coronary artery, n (%)       | 277 (5.0)                   | 118 (3.6)                   | 0.002   |
| Left anterior descending artery, n (%)  | 2818 (51.2)                 | 1575 (48.0)                 | 0.003   |
| Left circumflex artery, n (%)          | 1184 (21.5)                 | 791 (24.1)                  | 0.005   |
| Right coronary artery, n (%)           | 1818 (33.1)                 | 1102 (33.6)                 | 0.626   |
| Type C lesion, n (%)                   | 1965 (35.7)                 | 1185 (36.1)                 | 0.733   |
| Bifurcation lesion, n (%)              | 1853 (33.7)                 | 1055 (32.1)                 | 0.132   |
| Chronic total occlusion lesion, n (%)  | 381 (6.9)                   | 264 (8.0)                   | 0.053   |
| Balloon angioplasty, n (%)             | 912 (16.6)                  | 528 (16.1)                  | 0.539   |
| Bare metal stent, n (%)                | 829 (15.1)                  | 457 (13.9)                  | 0.143   |

(Continued)
CI-AKI incidence demonstrated a reverse J-curve relationship. Third, physicians were noted to tend toward the use of higher V/CrCl ratios in lean patients, particularly in those with a higher CI-AKI; physicians appear to focus on the absolute volume of contrast used, not on the V/CrCl ratio. Greater consideration of these factors will allow physicians to identify patients who are most at risk for CI-AKI and, therefore, limit the CV used during PCI procedures, especially in lean patients.

CI-AKI after PCI remains a major post-procedural complication due to its significant association with mortality, particularly among low-BMI patients [1,2,31]. However, providing adequate hydration and minimizing CVs are proven strategies for lowering the CI-AKI risk. In our study, a reverse J-curve relationship was observed between BMI and CI-AKI incidence. Hence, this identification of the effects of BMI on the incidence of CI-AKI may contribute to the ability of physicians to prevent CI-AKI. Conventionally, physicians often try to use the least amount of contrast possible, but higher volumes may be required in more complex cases. To eliminate the effects of these confounders, in the present study, we performed multivariate

Table 1. (Continued)

|                      | BMI ≤25 low-BMI group | BMI >25 high-BMI group | P-value |
|----------------------|-----------------------|------------------------|---------|
| Drug eluting stent, n (%) | 4243 (77.2)          | 2581 (78.6)           | 0.112   |
| Rotablator use, n (%)     | 147 (2.7)             | 80 (2.4)              | 0.499   |
| Use of intravascular ultrasound, n (%) | 4677 (85.1)   | 2785 (84.8)          | 0.779   |
| PCI for multi-vessels, n (%)   | 525 (9.5)          | 294 (9.0)            | 0.356   |
| Contrast volume (mL)    | 166 ± 74             | 174 ± 82             | <0.001  |
| V/CrCl>3, n (%)         | 2051 (37.3)          | 670 (20.4)           | <0.001  |

In-hospital outcomes

|                      | In-hospital mortality, n (%) | All complications, n (%) | Coronary dissection, n (%) | Coronary perforation, n (%) | Myocardial infarction, n (%) | Cardiogenic shock, n (%) | Heart failure, n (%) | Cerebral infarction, n (%) | Intracranial hemorrhage, n (%) | Cardiac tamponade, n (%) | Hemodialysis, n (%) | Transfusion, n (%) | Bleeding all, n (%) | Puncture site bleeding, n (%) | Puncture site hematoma, n (%) | Peritoneal bleeding, n (%) | Gastrointestinal bleeding, n (%) | Genitourinary bleeding, n (%) | Other bleeding, n (%) | Contrast induced acute kidney injury, n (%) | P-value |
|----------------------|---------------------------|------------------------|---------------------------|-----------------------------|-----------------------------|-------------------------|------------------------|-----------------------------|-----------------------------|--------------------------|-------------------|-----------------|-----------------|---------------------------|-----------------------------|-------------------------|-----------------------------|-----------------------------|----------------------|-----------------------------|---------|
|                      | 103 (1.9)                 | 50 (1.5)               | 232 (7.1)                 | 30 (0.9)                    | 44 (1.3)                   | 51 (1.6)                | 41 (1.2)               | 8 (0.2)                    | 2 (0.06)                    | 8 (0.2)                  | 38 (1.2)          | 50 (1.5)         | 69 (2.1)        | 15 (0.5)                   | 13 (0.4)                   | 2 (0.06)                | 9 (0.3)                    | 1 (0.03)                   | 34 (1.0)              | 313 (9.5)                  | 0.714   |
|                      | 145 (2.6)                 | 50 (1.5)               | 232 (7.1)                 | 30 (0.9)                    | 44 (1.3)                   | 51 (1.6)                | 41 (1.2)               | 8 (0.2)                    | 2 (0.06)                    | 8 (0.2)                  | 38 (1.2)          | 50 (1.5)         | 69 (2.1)        | 15 (0.5)                   | 13 (0.4)                   | 2 (0.06)                | 9 (0.3)                    | 1 (0.03)                   | 34 (1.0)              | 313 (9.5)                  | 0.001   |

BMI, body mass index; PCI, percutaneous coronary intervention; V/CrCl, contrast volume to creatinine clearance ratio

https://doi.org/10.1371/journal.pone.0203352.t001
logistic regression analyses to assess the predictors of \( \text{V/CrCl}>3 \), including complex treatment scenarios such as PCI of the left main coronary artery, type C lesions, bifurcations, chronic total occlusions, Rotablator use, and multivessel PCIs. Moreover, we excluded these complex cases when conducting a sensitivity analysis. The results demonstrated that physicians tend to use higher \( \text{V/CrCl} \) ratios in lean patients [29]. Since a \( \text{V/CrCl}>3 \) was strongly associated with CI-AKI in the low-BMI group, in our study, physicians need to recognize the role of CrCl values and attempt more rigorous intra-procedural CV reductions in lean patients; the use of biplane angiography, careful minimization of contrast injection, and the use of intravascular ultrasound guidance should be considered [7,32].

To distinguish between the high- and low-BMI groups, in this study, the BMI cut off was set at 25 kg/m\(^2\) because the mean BMI for Asian patients undergoing PCI is approximately 25 kg/m\(^2\), lower than for Western populations [33,34]. However, the obesity paradox has been observed in both Asian and Western patients undergoing PCI [34,35]. In addition, we showed that the relationship between BMI and CI-AKI incidence follows a reverse J-curve relationship. Because the number of elderly people undergoing PCI is increasing, and the average body habitus is getting leaner in aging societies [36,37], a focus on relatively lean patients (BMI <25 kg/m\(^2\)) is needed to improve in-hospital outcomes. Since we observed a tendency for physicians to use higher \( \text{V/CrCl} \)s in lean patients in the present real-world registry, the need for high CVs, relative to patient CrCl, should be carefully considered.

Previously, Amin et al. showed that the administered CVs were not different across patients, despite variations in CI-AKI risk. This was presumed to be because physicians focus on absolute CVs and not on the V/CrCl ratio [28]. We believe that this is the reason why V/

### Table 2. A multivariate logistic regression analysis of contrast induced acute kidney injury in the low-BMI group.

|                        | Odds ratio (confidential interval) | P-value |
|------------------------|-----------------------------------|---------|
| Female                 | 0.91 (0.71–1.15)                  | 0.42    |
| BMI                    | 1.01 (0.96–1.05)                  | 0.83    |
| Previous heart failure | 1.54 (1.13–2.11)                  | 0.007   |
| Diabetes mellitus      | 1.38 (1.13–1.70)                  | 0.002   |
| Peripheral artery disease | 1.64 (1.21–2.23)                  | 0.001   |
| Hypertension           | 1.64 (1.28–2.10)                  | <0.001  |
| Smoking                | 1.38 (1.10–1.73)                  | 0.005   |
| Previous PCI           | 0.74 (0.57–0.95)                  | 0.019   |
| Heart failure at admission | 1.72 (1.35–2.20)                  | <0.001  |
| Cardiogenic shock at admission | 1.14 (0.76–1.72)                  | 0.53    |
| Cardiopulmonary arrest at admission | 1.36 (0.82–2.26)                  | 0.24    |
| Femoral artery approach | 1.60 (1.28–2.01)                  | <0.001  |
| Intra-aortic balloon pump | 2.48 (1.87–3.30)                  | <0.001  |
| ST-elevation myocardial infarction | 4.52 (3.41–5.98)                  | <0.001  |
| Non-ST-elevation myocardial infarction | 2.98 (2.10–4.23)                  | <0.001  |
| Unstable angina        | 1.46 (1.03–2.05)                  | 0.032   |
| Type C lesion          | 1.39 (1.13–1.71)                  | 0.002   |
| Use of intravascular ultrasound | 0.85 (0.66–1.09)                  | 0.20    |
| V/CrCl>3               | 1.77 (1.42–2.21)                  | <0.001  |
| Age                    | 1.03 (1.02–1.04)                  | <0.001  |

BMI, body mass index; PCI, percutaneous coronary intervention; V/CrCl, contrast volume to creatinine clearance ratio

https://doi.org/10.1371/journal.pone.0203352.t002
Table 3. Multivariate logistic regression analysis of contrast induced acute kidney injury in the high-BMI group.

|                              | Odds ratio (confidential interval) | P-value |
|------------------------------|------------------------------------|---------|
| Female                       | 0.99 (0.70–1.41)                   | 0.96    |
| BMI                          | 1.01 (0.97–1.06)                   | 0.58    |
| Previous heart failure       | 1.24 (0.74–2.08)                   | 0.42    |
| Diabetes mellitus            | 1.19 (0.91–1.55)                   | 0.20    |
| Peripheral artery disease    | 1.62 (0.98–2.68)                   | 0.062   |
| Hypertension                 | 1.56 (1.10–2.21)                   | 0.013   |
| Smoke                        | 1.06 (0.80–1.42)                   | 0.68    |
| Previous PCI                 | 0.73 (0.52–1.02)                   | 0.066   |
| Heart failure upon admission | 1.51 (1.04–2.20)                   | 0.031   |
| Cardiogenic shock upon admission | 1.20 (0.66–2.19)                       | 0.54    |
| Cardiopulmonary arrest upon admission | 3.40 (1.79–6.45)                        | <0.001  |
| Femoral artery approach      | 1.34 (1.01–1.78)                   | 0.042   |
| Intra-aortic balloon pump    | 3.39 (2.30–5.00)                   | <0.001  |
| ST-elevation myocardial infarction | 4.55 (3.17–6.55)                       | <0.001  |
| Non-ST-elevation myocardial infarction | 2.95 (1.84–4.73)                        | <0.001  |
| Unstable angina              | 1.40 (0.90–2.78)                   | 0.14    |
| Type C lesion                | 0.90 (0.68–1.20)                   | 0.48    |
| Use of intravascular ultrasound | 0.86 (0.61–1.20)                       | 0.37    |
| V/CrCl > 3                   | 1.67 (1.22–2.29)                   | 0.001   |
| Age                          | 1.02 (1.01–1.04)                   | <0.001  |

BMI, body mass index; PCI, percutaneous coronary intervention; V/CrCl, contrast volume to creatinine clearance ratio

https://doi.org/10.1371/journal.pone.0203352.t003

Fig 2. Smooth spline plots of BMIs and CI-AKI incidence rates. The smooth spline is shown as a blue line and the gray area represents the 95% confidence intervals. BMI, body mass index; CI-AKI, contrast-induced acute kidney injury.

https://doi.org/10.1371/journal.pone.0203352.g002
CrCl ratios $< 3$ were not achieved, especially in lean patients. We also demonstrated that patients with a higher CI-AKI risk tend to have higher V/CrCl ratios, especially patients with a low BMI; this is contrary to the guideline recommendation [4]. The V/CrCl ratio is a well-established and internationally validated index, developed to decrease the risk of CI-AKI (with a target $< 3$) [5,7]. However, the actual CV used during PCI procedures differs among currently practicing physicians [28]. This study, in addition to improving the ability of physicians to recognize patients with higher CI-AKI risks, provides physicians with feedback regarding the value of this index from a large-scale, national registry data investigation [20,28,38].

We also showed a higher incidence of CI-AKI in obese patients, based on the reverse J-curve relationship between BMI and CI-AKI incidence. Buschur et al. [39] found that poor fluoroscopic visualization and miscalculation of renal function is common in obese patients. We believe that a vulnerability to contrast media and an erroneous estimation of renal function are responsible for this phenomenon. The greater vulnerability to contrast media, among obese individuals, might be attributed to hyperleptinemia, increased sympathetic activity, hypoadiponectinemia, and high levels of free fatty acids and endothelin-1 [40].

There are several limitations in our study. First, this was a prospective, observational study. The non-randomized of the study; the effects of unmeasured confounders; and the potential for selection bias and surgeon bias to exist, even after adjustment, might have influenced the multivariate analysis outcomes. Second, although the registry includes a relatively large
number of PCI procedures, performed at multiple centers, not all hospitals in Japan participate in the registry. Further, not all participating hospitals were fully investigated throughout the study period. However, the characteristics of the patients in our registry were similar to those in the national PCI registry [23,41]. Further, compared to the NCDR registry [19], the patients in our registry were older, included a higher proportion of males, and had a higher overall proportion of individuals with diabetes, a positive smoking status, and more complex lesions. Despite these differences, the mortality risk and CI-AKI models derived from the NCDR registry were able to be correctly applied to our registry [23]. Therefore, we believe that our registry is one of the most representative PCI databases in Japan. Further, our results provide the most

Table 4. Multivariate logistic regression analysis for V/CrCl>3.

| Variable                                      | Odds ratio (confidence interval) | P value |
|-----------------------------------------------|----------------------------------|---------|
| Age                                           | 1.05 (1.04–1.06)                 | <0.001  |
| Female                                        | 1.36 (1.19–1.55)                 | <0.001  |
| Creatinine clearance <60 mL/min               | 4.30 (3.78–4.90)                 | <0.001  |
| BMI (one unit decrement)                      | 1.08 (1.05–1.10)                 | <0.001  |
| Previous myocardial infarction                | 1.19 (1.02–1.38)                 | 0.026   |
| Previous heart failure                        | 0.98 (0.81–1.19)                 | 0.83    |
| Cerebrovascular disease                       | 0.91 (0.75–1.09)                 | 0.30    |
| Peripheral artery disease                     | 1.32 (1.10–1.58)                 | 0.003   |
| Chronic lung disease                          | 1.11 (0.84–1.46)                 | 0.48    |
| Hypertension                                  | 1.39 (1.21–1.59)                 | <0.001  |
| Smoking                                       | 1.12 (0.98–1.27)                 | 0.093   |
| Dyslipidemia                                  | 1.02 (0.91–1.16)                 | 0.70    |
| Previous PCI                                  | 0.84 (0.73–0.97)                 | 0.016   |
| Previous coronary bypass                      | 1.37 (1.07–1.74)                 | 0.012   |
| Heart failure upon admission                  | 1.22 (1.03–1.45)                 | 0.025   |
| Cardiogenic shock upon admission              | 1.06 (0.75–1.49)                 | 0.75    |
| Cardiopulmonary arrest upon admission         | 1.16 (0.77–1.76)                 | 0.49    |
| Femoral artery approach                       | 2.19 (1.95–2.47)                 | <0.001  |
| Intra-aortic balloon pump                     | 1.67 (1.32–2.11)                 | <0.001  |
| ST-elevation myocardial infarction            | 0.89 (0.76–1.05)                 | 0.160   |
| Non-ST-elevation myocardial infarction        | 0.97 (0.78–1.20)                 | 0.77    |
| Unstable angina                               | 1.22 (1.04–1.43)                 | 0.015   |
| 3-vessel disease                              | 1.13 (0.98–1.29)                 | 0.093   |
| PCI of the left main coronary artery           | 1.06 (0.81–1.38)                 | 0.68    |
| PCI of the left anterior descending artery     | 1.21 (1.07–1.38)                 | 0.003   |
| PCI of the left circumflex artery             | 1.15 (0.99–1.34)                 | 0.070   |
| Type C lesion                                 | 1.21 (1.07–1.37)                 | 0.003   |
| Bifurcation lesion                            | 1.36 (1.20–1.54)                 | <0.001  |
| Chronic total occlusion lesion                | 2.79 (2.25–3.46)                 | <0.001  |
| Rotablator use                                | 1.59 (1.15–2.19)                 | 0.005   |
| Multi-vessel PCI                              | 1.69 (1.38–2.07)                 | <0.001  |

V/CrCl, contrast volume to creatinine clearance ratio; BMI, body mass index; PCI, percutaneous coronary intervention

https://doi.org/10.1371/journal.pone.0203352.t004
complete assessment of current practice patterns in Japan, and the results may be applied globally. Third, we excluded patients with missing baseline and post-procedural BMI, creatinine, and CV values; the data for the missing patients are included in S1 and S2 Tables. Since creatinine values were not consistently collected from stable patients, missing values were more often associated with these patients; thus, these exclusions may have biased our results. Fourth, the causes of post-PCI CI-AKI are multifactorial [42], and the use of contrast agents is only one of the causes. We also identified acute coronary syndrome and the use of intra-aortic balloon pumps as additional risk factors associated with the development of CI-AKI. Finally, BMI might be a confounder of the relationship between the V/CrCl ratio and CI-AKI incidence because the low-BMI patients had low CrCl values, as shown in our study. Patients with low body weights also tend to have higher V/CrCl ratios. However, BMI is not equivalent to body weight, and the association of BMI with CrCl is complex because it does not demonstrate a positive correlation after adjustment for total body surface area [43]. Moreover, CrCl was estimated, using the Cockcroft-Gault equation, to be higher in lean patients than in other patients because of their lower muscle mass; this indicates that BMI and CrCl are not positively correlated [44]. Because of the complicated relationship between BMI and CrCl, the ability to demonstrate an association between the V/CrCl ratio and BMI is valuable.

Fig 4. Mean V/CrCl ratio compared to AKI risk decile for all patients, the low-BMI group, and the high-BMI group. V/CrCl, contrast volume to creatinine clearance ratio; AKI, acute kidney injury; BMI, body mass index.

https://doi.org/10.1371/journal.pone.0203352.g004
In conclusion, a V/CrCl > 3 was associated with CI-AKI in patients with low (≤ 25 kg/m²) and high (> 25 kg/m²) BMIs, and the relationship between BMI and CI-AKI incidence followed a reverse J-curve relationship. Importantly, we identified a tendency for physicians to use high V/CrCl ratios in patients with low BMIs, particularly in those with higher CI-AKI risk. This is believed to occur because physicians focus on the absolute amount of CV used, rather than on the V/CrCl ratio. Furthermore, high V/CrCl ratios in low-BMI patients remained unchanged after we excluded complex cases. The identification of the BMI effects on CI-AKI incidence might improve the ability of physicians to prevent CI-AKI by selecting more optimal CVs for each patient.

Supporting information
S1 Table. Baseline characteristics all records excluding patients on dialysis. (DOCX)
S2 Table. In-hospital outcomes of all records excluding patients on dialysis. (DOCX)

Acknowledgments
The authors thank all the investigators, clinical coordinators, and institutions involved in the JCD-KiCS.

Investigators
Yohei Numasawa, Masaki Kodaira, Ryota Tabei (Japanese Red Cross Ashikaga Hospital), Yutaka Okada (Eiju General Hospital), Soushin Inoue, Iwao Nakamura (Hino Municipal Hospital), Takaharu Katayama, Shunsuke Takagi, Takashi Matsubara (Hiiratsuka City Hospital), Masashi Takahashi, Keishu Li, Koichiro Sueyoshi (Kawasaki City Municipal Hospital), Taku Inohara, Fumiaki Yashima, Atsushi Anzai, Kentaro Hayashida, Takashi Kawakami, Hideaki Kanazawa, Shunsuke Yuasa, Yuichiro Maekawa (Keio University School of Medicine), Masahiro Suzuki, Keisuke Matsumura (National Hospital Organization Saitama National Hospital) Yukinori Ikegami, Jun Fuse, Munehisa Sakamoto, Yukihiro Momiyama (National Hospital Organization Tokyo Medical Center), Ayaka Endo, Tasuku Hasegawa, Toshiyuki Takahashi, Susumu Nakagawa (Saiseikai Central Hospital), Takashi Yagi, Koji Ueno, Kenichiro Shimoji, Shigetaka Noma (Saiseikai Utsunomiya Hospital), Masahito Munakata, Takashi Akima, Shiro Ishikawa, Takashi Koyama (Saitama City Hospital), Atsushi Mizuno, Yutaro Nishi (St Luke’s International Hospital Heart Center), Toshimi Kageyama, Kazunori Moritani, Masaru Shibata (Tachikawa Kyosai Hospital), Kimi Koide, Yoshinori Mano, Takahiro Oki (Tokyo Dental College Ichikawa General Hospital), Daisuke Shinmura, Koji Negishi, Yusuke Jo, and Takahiro Koura (Yokohama Municipal Hospital)

Clinical coordinators
Junko Susa, Ayano Amagawa, Hiroaki Nagayama, Miho Umemura, Itsuka Saito, and Ikuko Ueda.

Author Contributions
Conceptualization: Toshiki Kuno, Yohei Numasawa, Mitsuaki Sawano, Masaki Kodaira, Shigetaka Noma, Koji Negishi, Shiro Ishikawa, Hiroaki Miyata, Keiichi Fukuda, Shun Kohsaka.
Data curation: Toshiki Kuno, Yohei Numasawa, Mitsuaki Sawano, Masaki Kodaira, Ikuko Ueda, Masahiro Suzuki, Shigetaka Noma, Koji Negishi, Shiro Ishikawa, Hiroaki Miyata, Keiichi Fukuda, Shun Kohsaka.

Formal analysis: Toshiki Kuno, Mitsuaki Sawano, Toshiomi Katsuki, Masaki Kodaira, Ikuko Ueda, Hiroaki Miyata, Shun Kohsaka.

Funding acquisition: Shun Kohsaka.

Investigation: Toshiki Kuno, Mitsuaki Sawano, Toshiomi Katsuki, Masaki Kodaira, Ikuko Ueda, Masahiro Suzuki, Shigetaka Noma, Koji Negishi, Shiro Ishikawa, Hiroaki Miyata, Keiichi Fukuda, Shun Kohsaka.

Methodology: Toshiki Kuno, Mitsuaki Sawano, Masaki Kodaira, Ikuko Ueda, Masahiro Suzuki, Shigetaka Noma, Koji Negishi, Shiro Ishikawa, Hiroaki Miyata, Keiichi Fukuda, Shun Kohsaka.

Project administration: Toshiki Kuno, Yohei Numasawa, Mitsuaki Sawano, Masaki Kodaira, Masahiro Suzuki, Shigetaka Noma, Koji Negishi, Shiro Ishikawa, Hiroaki Miyata, Keiichi Fukuda, Shun Kohsaka.

Resources: Toshiki Kuno, Yohei Numasawa, Mitsuaki Sawano, Toshiomi Katsuki, Masaki Kodaira, Masahiro Suzuki, Shigetaka Noma, Koji Negishi, Shiro Ishikawa, Hiroaki Miyata, Keiichi Fukuda, Shun Kohsaka.

Software: Toshiki Kuno, Toshiomi Katsuki, Hiroaki Miyata.

Supervision: Yohei Numasawa, Mitsuaki Sawano, Toshiomi Katsuki, Masaki Kodaira, Ikuko Ueda, Masahiro Suzuki, Shigetaka Noma, Koji Negishi, Hiroaki Miyata, Keiichi Fukuda, Shun Kohsaka.

Validation: Toshiki Kuno, Yohei Numasawa, Mitsuaki Sawano, Masaki Kodaira, Ikuko Ueda, Masahiro Suzuki, Hiroaki Miyata, Keiichi Fukuda, Shun Kohsaka.

Visualization: Toshiki Kuno, Mitsuaki Sawano, Masaki Kodaira.

Writing – original draft: Toshiki Kuno, Shun Kohsaka.

Writing – review & editing: Toshiki Kuno, Yohei Numasawa, Mitsuaki Sawano, Toshiomi Katsuki, Masaki Kodaira, Ikuko Ueda, Masahiro Suzuki, Shigetaka Noma, Koji Negishi, Shiro Ishikawa, Hiroaki Miyata, Keiichi Fukuda, Shun Kohsaka.

References

1. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002; 105: 2259–2264. PMID: 12010907.

2. Marenzi G, Lauri G, Assanelli E, Campodónico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004; 44: 1780–1785. https://doi.org/10.1016/j.jacc.2004.07.043 PMID: 15519007.

3. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51: 1419–1428. https://doi.org/10.1016/j.jacc.2007.12.035 PMID: 18402894.

4. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr., Ettinger SM, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011; 57: 1920–1959. https://doi.org/10.1016/j.jacc.2011.02.009 PMID: 21450428.
Contrast-induced acute kidney injury and body mass index

5. Kooiman J, Seth M, Share D, Dixon S, Gurm HS. The association between contrast dose and renal complications post PCI across the continuum of procedural estimated risk. PloS ONE. 2014; 9: e90233. https://doi.org/10.1371/journal.pone.0090233 PMID: 24625555.

6. Baiermans CE, Reichert LJ, van Schelven BI, van den Brand JA, Wetzelis JF. Epidemiology of contrast material-induced nephropathy in the era of hydration. Radiology. 2012; 263: 706–713. https://doi.org/10.1148/radiol.12111667 PMID: 22535561.

7. Gurm HS, Dixon SR, Smith DE, Share D, Lalonde T, Greenbaum A, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011; 58: 907–914. https://doi.org/10.1016/j.jacc.2011.05.023 PMID: 21851878.

8. Ohno Y, Maekawa Y, Miyata H, Inoue S, Ishikawa S, Sueyoshi K, & al. Impact of periprocedural bleeding on incidence of contrast-induced acute kidney injury in patients treated with percutaneous coronary intervention. J Am Coll Cardiol. 2013; 62: 1260–1266. https://doi.org/10.1016/j.jacc.2013.03.086 PMID: 23770181.

9. Kuno T, Kohsaka S, Numasawa Y, Ueda I, Suzuki M, Nakamura I, & al. Location of the culprit coronary lesion and its association with delay in door-to-balloon time (from a multicenter registry of primary percutaneous coronary intervention). Am J Cardiol. 2015; 115: 581–586. https://doi.org/10.1016/j.amjcard.2014.12.004 PMID: 25577426.

10. Hirota Y, Sawano M, Numasawa Y, Ueda I, Noma S, Suzuki M, & al. Characteristics and in-hospital outcomes in young patients presenting with acute coronary syndrome treated by percutaneous coronary intervention. Cardiovasc Interv Ther. 2018; 33: 154–162. https://doi.org/10.1007/s12929-017-0471-z PMID: 28585049.

11. Ikemura N, Sawano M, Shiraishi Y, Ueda I, Miyata H, Numasawa Y, & al. Barriers associated with door-to-balloon delay in contemporary Japanese practice. Curr J. 2017; 81: 815–822. https://doi.org/10.1253/circj.CJ-16-0095 PMID: 28228609.

12. Kodaira M, Miyata H, Numasawa Y, Ueda I, Maekawa Y, Sueyoshi K, & al. Effect of smoking status on clinical outcome and efficacy of clopidogrel in acute coronary syndrome. Circ J. 2016; 80: 1530–1539. https://doi.org/10.1253/circj.CJ-16-0032 PMID: 27245240.

13. Ikegami Y, Kohsaka S, Miyata H, Ueda I, Fuse J, Sakamoto M, & al. Outcomes of percutaneous coronary intervention performed with or without preprocedural dual antiplatelet therapy. Circ J. 2015; 79: 2598–2607. https://doi.org/10.1253/circj.CJ-15-0484 PMID: 26447105.

14. Kuno T, Numasawa Y, Miyata H, Takahashi T, Sueyoshi K, Ohki T, & al. Impact of coronary dominance on in-hospital outcomes after percutaneous coronary intervention in patients with acute coronary syndrome. PloS ONE. 2013; 8: e72672. https://doi.org/10.1371/journal.pone.0072672 PMID: 23991136.

15. Numasawa Y, Kohsaka S, Miyata H, Kawamura A, Noma S, Suzuki M, & al. Impact of body mass index on in-hospital complications in patients undergoing percutaneous coronary intervention in a Japanese real-world multicenter registry. PloS ONE. 2015; 10: e0124399. https://doi.org/10.1371/journal.pone.0124399 PMID: 25874887.

16. Numasawa Y, Kohsaka S, Miyata H, Noma S, Suzuki M, Ishikawa S, & al. Gender differences in in-hospital clinical outcomes after percutaneous coronary interventions: an insight from a Japanese multicenter registry. PloS ONE. 2015; 10: e0116496. https://doi.org/10.1371/journal.pone.0116496 PMID: 25635905.

17. Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, & al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol. 2010; 56: 254–263. https://doi.org/10.1016/j.jacc.2010.05.008 PMID: 20633817.

18. Anderson HV, Shaw RE, Brindis RG, McKay CR, Klein LW, Krone RJ, & al. Risk-adjusted mortality analysis of percutaneous coronary interventions by American College of Cardiology/American Heart Association guidelines recommendations. Am J Cardiol. 2007; 99: 189–196. https://doi.org/10.1016/j.amjcard.2006.07.083 PMID: 17224177.

19. Kohsaka S, Miyata H, Ueda I, Masoudi FA, Peterson ED, Maekawa Y, & al. An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KICS). Am Heart J. 2015; 170: 1077–1085. https://doi.org/10.1016/j.ahj.2015.09.017 PMID: 26678628.

20. Inohara T, Kohsaka S, Yamaji K, Amano T, Fuji K, Oda H, & al. Impact of Institutional and Operator Volume on Short-Term Outcomes of Percutaneous Coronary Intervention: A Report From the Japanese Nationwide Registry. JACC Cardiovascular Interventions. 2017 May 8; 10(9):918–27. https://doi.org/10.1016/j.jcin.2017.02.015 PMID: 28473114.

21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41. https://doi.org/10.1159/000180580 PMID: 1244584.
22. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, et al. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry. J Am Heart Assoc. 2014; 3:e001380. https://doi.org/10.1161/JAHA.114.001380 PMID: 25516439.

23. Inohara T, Kohsaka S, Miyata H, Ueda I, Maekawa Y, Fukuda K, et al. Performance and validation of the U.S. NCDR acute kidney injury prediction model in Japan. J Am Coll Cardiol. 2016; 67: 1715–1722. https://doi.org/10.1016/j.jacc.2016.01.049 PMID: 27056778.

24. Mehta RL, Kellum JA, Shah SV, Mollitoris BA, Ronco C, Warnock DG, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123: 2736–2747. https://doi.org/10.1161/CIRCULATIONAHA.110.009449 PMID: 21670242.

25. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med. 2003; 4 Suppl 5: S3–S9. PMID: 14668704.

26. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2009; 2:222–229. https://doi.org/10.1161/CIRCINTERVENTIONS.108.846741 PMID: 20031719.

27. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123: 2736–2747. https://doi.org/10.1161/CIRCULATIONAHA.110.009449 PMID: 21670242.

28. Amin AP, Bach RG, Caruso ML, Kennedy KF, Spertus JA. Association of variation in contrast volume with acute kidney injury in patients undergoing percutaneous coronary intervention. JAMA Cardiol. 2017; 2: 1007–1012. https://doi.org/10.1001/jamacardio.2017.2156 PMID: 28679898.

29. Endo A, Kawamura A, Miyata H, Noma S, Suzuki M, Koyama T, et al. Angiographic lesion complexity score and in-hospital outcomes after percutaneous coronary intervention. PloS ONE. 2015; 10: e0127217. https://doi.org/10.1371/journal.pone.0127217 PMID: 26121583.

30. Yang SC, Fu NK, Zhang J, Liang M, Cong HL, Lin WH, et al. Preventive effects of alprostadil against contrast-induced nephropathy in patients with renal insufficiency undergoing percutaneous coronary intervention. Angiology. 2018; 69: 393–399. https://doi.org/10.1177/0003319717730942 PMID: 28073785.

31. Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol. 2002; 39:578–584. PMID: 11849854.

32. Mariani J Jr., Guedes C, Soares P, Zalc S, Campos CM, Lopes AC, et al. Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utilZation With IVUS Guidance in coRonary angioplasty) randomized controlled trial. JACC Cardiovasc Interv. 2014; 7: 1287–1293. https://doi.org/10.1016/j.jcin.2014.05.024 PMID: 25326742.

33. Kunimura A, Ishii H, Uetani T, Aoki T, Harada K, Hirayama K, et al. Impact of nutritional assessment and body mass index on cardiovascular outcomes in patients with stable coronary artery disease. Int J Cardiol. 2017; 230: 653–658. https://doi.org/10.1016/j.ijcard.2017.01.008 PMID: 28077227.

34. Angeras O, Albertsson P, Karason K, Ramunddal T, Matejka G, James S, et al. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J. 2013; 34:345–353. https://doi.org/10.1093/eurheartj/ehs217 PMID: 22947610.

35. Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, et al. Obesity paradox in Japanese patients after percutaneous coronary intervention: an observation cohort study. J Cardiol. 2013; 62: 18–24. https://doi.org/10.1016/j.jjc.2013.02.009 PMID: 23706354.

36. Miller SL, Wolfe RR. The danger of weight loss in the elderly. J Nutr Health Aging. 2008; 12: 487–491. PMID: 18615231.

37. Claessens BE, Kikkert WJ, Engstrom AE, Hoenbers LP, Damman P, Vis MM, et al. Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. Heart. 2010; 96: 843–847. https://doi.org/10.1136/hrt.2009.185678 PMID: 19961111.

38. Hao Y, Liu J, Liu J, Smith SC Jr., Huy O, Fonarow GC, et al. Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome. Am Heart J. 2016; 179: 107–115. https://doi.org/10.1016/j.ahj.2016.06.005 PMID: 27595685.
Ji L, Su X, Qin W, Mi X, Liu F, Tang X, et al. Novel risk score of contrast-induced nephropathy after percutaneous coronary intervention. Nephrology. 2015; 20: 544–551. https://doi.org/10.1111/nep.12429 PMID: 25706048.

Inohara T, Numasawa Y, Higashi T, Ueda I, Suzuki M, Hayashida K, et al. Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviews the influence of procedural complications. Am Heart J. 2017; 194: 61–72. https://doi.org/10.1016/j.ahj.2017.08.008 PMID: 29223436.

Shacham Y, Steinvil A, Arbel Y. Acute kidney injury among ST elevation myocardial infarction patients treated by primary percutaneous coronary intervention: a multifactorial entity. J Nephrol. 2016; 29: 169–174. https://doi.org/10.1007/s40620-015-0255-4 PMID: 26861658.

Afsar B, Elsurer R, Guner E, Kirkpantur A. Which anthropometric parameter is best related with urinary albumin excretion and creatinine clearance in type 2 diabetes: body mass index, waist circumference, waist-to-hip ratio, or conicity index? J Renal Nutr. 2011; 21: 472–478. https://doi.org/10.1053/j.jrn.2010.12.003 PMID: 21454092.

Dekur-Smielecka E, Kotlinska-Lemieszek A, Chudek J, Wieczorowska-Tobis K. Assessment of renal function in geriatric palliative care patients—comparison of creatinine-based estimation equations. Clin Interv Aging. 2017; 12: 977–983. https://doi.org/10.2147/CIA.S130583 PMID: 28694691.